European Diagnostic Manufacturers Association EDMA Presentation 2007 Jean-François de Lavison President of EDMA Mérieux Alliance Geneva, Retooling Task Force January, 2008

2 Geneva, January 2008 European Healthcare Market in 2007 In Vitro Diagnostics 3.5% Radiological, Electro-medical & Healthcare IT 3.5% Medical Devices 25% Pharmaceuticals 68%

3 Geneva, January 2008 EDMA Members 30 Corporate Associated Members From 15 to Cellestis Chiron Genzyme Tosoh 2007 Biosystems FIND Diagnostics Innogenetics Luminex Mallinkrodt MLT Orion Randox Siemens Diagnostics STAGO TECAN Philips

4 Geneva, January 2008 EDMA Members 21 National Association Members Working to develop new IVD associations From 20 to Turkey

5 Geneva, January 2008 EDMA Mission  To raise awareness of the added-value that diagnostic information can provide to health,  To support an appropriate regulatory system,  To work towards a realistic economic environment for healthcare, and  To be an effective voice in globalisation.

Advocating the value of IVDs European Diagnostic Manufacturers Association

7 Geneva, January 2008 The essential role of IVDs DISEASE Diagnosis Therapy Prevention Screening targeted populations »Correct and early diagnosis is the key to effective & sustainable healthcare in the medium-long term.  IVDs represent less than 2% of the Total Health Expenditure, which is less than €20 per capita and per annum (EDMA 2005 European Market Estimates) and its information influences about 64% of the medical decisions (JD. Kruse-Jarrest, Lab. Med. 18:213/1994)    EDMA is campaigning to present laboratory testing as a valuable asset that is a cost-effective component of health maintenance and disease management. Early & Correct Diagnosis is key to effective therapy IVDs provide objective information in evaluating the effects of treatment

8 Geneva, January 2008 Example: Tuberculosis Clinical Benefit  New IVD tests offer, for the first time, the opportunity to stop TB infection before it progresses to disease.  IVDs allows an earlier detection of the pathogen agent, an earlier start of an adapted treatment, and in most of the cases an earlier recovery. Economic Benefit  Direct economic impact of tuberculosis in the EU is estimated to be more than €1 billion.  Treatment of MDR-TB requires up to 2 years of chemotherapy, which is more than 100 times more expensive than treatment of drug- susceptible TB Patient Benefit  Faster diagnosis means patients can be better managed at an earlier stage, resulting in Europe has the highest rate of multidrug-resistant tuberculosis (MDR-TB) in the world, with nearly 70,000 cases per year. Virtually untreatable strains are emerging in Eastern Europe.  better control of the spread of TB,  avoidance of unnecessary suffering of patients, and their families/carers  more efficient utilisation of hospital resources Draft messages: Work in progress

9 Geneva, January 2008  Mar 07, Brussels: ECDC Scientific Seminar »EDMA represented IVD sector interests »Contacts established with WHO, Stop TB Partnership, ECDC, etc.  Follow-up Meetings with all stakeholders »Objective: Discuss common actions to define and implement appropriate measures to fight TB  Sep 07, Lisbon: Portuguese Presidency Conference on ‘Health & Migration’ -EDMA to attend and propose participation  22 October 2007, Berlin: High Level Ministerial Forum “TB is a regional emergency” »Organised by WHO-Europe, in cooperation with the EU, ECDC, Stop TB Partnership, among other stakeholders -EDMA to attend and propose a speaker -Provide input for the future WHO TB Action Plan for Europe TB Advocacy Actions

10 Geneva, January 2008 Soon available in Italian June, Turin in Hungarian September + Global access to all sites Lab Tests Online Spain: Germany: Poland: Combined Traffic: Over 35,000 unique visitors in May Also available in the future in Portuguese and Czech

EDMA represents the In Vitro Diagnostics Industry in Europe Visit our website: Place des Maïeurs Brussels Belgium Tel Fax European Diagnostic Manufacturers Association